Dr. Wei Han completed his Ph.D. in Molecular Biology from Mount Sinai School of Medicine at NYC in 1994 followed by a postdoctoral training at Memorial Sloan-Kettering Cancer Center. He is now a professor at Shanghai Jiao Tong University and Founder of General Regeneratives (Shanghai) Ltd. He developed a proprietary “Prometheus Technology” to discover genes important for multiple tissue regeneration and repair, including bone marrow, liver, pancreas, cartilage, gut epithelial, and thymus. Over the years, a series of investigational new drugs were developed. The most advanced candidate with global patents, GR007, a multi-organ protector against chemotoxicities has demonstrated its good safety profile and preliminary efficacy in phase 1 clinical trial, and phase 2 clinical trial is ongoing.
Recent Comments